NeoGenomics to present new data at AMP 2024

NeoGenomics, Inc., a leading oncology testing services company, will present four abstracts at the Association for Molecular Pathology (AMP) 2024 Annual Meeting & Expo in Vancouver, Canada, November 19-23 (booth #830). The research demonstrates how ctDNA and next-generation sequencing (NGS) can drive more personalized and accurate treatment options for cancer patients.

NeoGenomics’ presentations include:

• A Solid Tumor Gene Fusion Next-Generation Sequencing Assay on the G4 Sequencing Platform
  • Abstract #1874602: Friday, November 22 | 9:15-10:15 a.m. PST
  • The study highlights the G4 platform as a reliable and efficient alternative for clinical and genomic research applications, delivering high accuracy, speed, and flexibility.
• Effect of Genomic DNA Contamination in Cell-Free DNA on the Assay Performance of TSO500 ctDNA v2
  • Abstract #1874288: Friday, November 22 | 9:15-10:15 a.m. PST
  • The data shows that the TSO500 ctDNA v2 assay maintains high sensitivity for detecting tumor mutations, even with significant genomic DNA contamination, ensuring reliable results for cancer profiling through liquid biopsy.
• An Enhanced Workflow for the Neo Comprehensive™ Solid Tumor Genome Profiling Assay: Comparison for Tecan Qubit vs KAPA Library Quantification
  • Abstract #1874050: Friday, November 22 | 9:15-10:15 a.m. PST
  • The study validates an improved workflow for the Neo Comprehensive™ solid tumor genome profiling NGS panel, offering significant time savings and reducing errors while maintaining equivalent accuracy and performance.
• Human Papillomavirus Subtyping Using Whole Transcriptome Sequencing
  • Abstract #1874277: Saturday, November 23 | 9:15-10:15 a.m. Pacific Time
  • The data demonstrates that NeoGenomics’ bioinformatics pipeline can identify and classify HPV cases into high and low-risk subtypes with similar performance to more traditional methods, delivering added value and potential cost savings for patients.

“Our presence at AMP 2024 underscores NeoGenomics’ dedication to advancing cancer care through ongoing research in precision medicine,” said Warren Stone, CCO of NeoGenomics. “By continuing to improve our methods and technologies, we aim to enhance outcomes and set new standards for oncology testing.”

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>